What is the 13F Pro Quality Score for OMDA?

13F Pro ranks Omada Health, Inc. (OMDA) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View OMDA's current score at https://13fpro.ai/research/OMDA (free sign-up required for the full ranking).

Where does 13F Pro source OMDA data?

All Omada Health, Inc. fundamentals and ownership data come directly from SEC EDGAR. Omada Health, Inc. files with the SEC under CIK 1611115. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is OMDA in?

Omada Health, Inc. (OMDA) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is OMDA research updated on 13F Pro?

OMDA's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Omada Health, Inc.(OMDA)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1611115 OMDA stock profile & AI dashboard →

13F Pro Quality Score

45.5/100

Rank #1,712 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

93.5/100

Profitability

30.0/100

Balance Sheet

30.0/100

Earnings Quality

30.0/100

Free Cash Flow

30.0/100

Institutional Flow

89.7/100

Revenue Scale

30.0/100

Dilution Risk

25.8/100

OMDA Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Omada Health, Inc. (OMDA), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores OMDA at 45.5/100 on a 32-signal composite quality model, placing it at rank #1,712 of 2,879 stocks — the bottom half of the AI-ranked universe. OMDA scores in the top quartile across revenue growth (93.5), institutional flow (89.7). Areas of concern include profitability (30.0) and balance sheet strength (30.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 25.8/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Omada Health, Inc. reports quarterly revenue of $78.0M, net income of $-3.0M, an operating margin of -6.1%. Top institutional holders of OMDA by reported 13-F value include Divisadero Street Capital Management,, Revelation Capital Management,, FMR, based on the most recent SEC filings. OMDA trades on the Nasdaq exchange and files with the SEC under CIK 1611115. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate OMDA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Omada Health, Inc. directly from SEC EDGAR.

Revenue

Q1 2026

$78.0M

Net Income

Q1 2026

$-3.0M

Free Cash Flow

Q1 2026

$-11.9M

Operating Margin

Q1 2026

-6.1%

ROIC

Q1 2026

-2.0%

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+53.2% YoY

$260.2MFY 2025

FY22 —FY23 $122.8MFY24 $169.8MFY25 $260.2M

Net Income

+72.9% YoY

$-12.8MFY 2025

FY22 —FY23 $-67.5MFY24 $-47.1MFY25 $-12.8M

Operating Income

+72.6% YoY

$-12.0MFY 2025

FY22 —FY23 $-66.0MFY24 $-43.7MFY25 $-12.0M

EPS (Diluted)

+59.9% YoY

$-0.35FY 2025

FY22 —FY23 $-1.36FY24 $-0.87FY25 $-0.35

Total Assets

+102.4% YoY

$305.4MFY 2025

FY22 —FY23 —FY24 $150.9MFY25 $305.4M

Total Debt

-100.0% YoY

$0.00FY 2025

FY22 —FY23 —FY24 $29.8MFY25 $0.00

Op. Cash Flow

+153.4% YoY

$18.3MFY 2025

FY22 —FY23 $-49.7MFY24 $-34.2MFY25 $18.3M

Metric	FY 2025	FY 2024	FY 2023	FY 2022
Revenue	$260.2M +53.2%	$169.8M +38.3%	$122.8M	—
Net Income	$-12.8M +72.9%	$-47.1M +30.2%	$-67.5M	—
Operating Income	$-12.0M +72.6%	$-43.7M +33.9%	$-66.0M	—
EPS (Diluted)	$-0.35 +59.9%	$-0.87 +35.8%	$-1.36	—
Total Assets	$305.4M +102.4%	$150.9M	—	—
Total Debt	$0.00 -100.0%	$29.8M	—	—
Operating Cash Flow	$18.3M +153.4%	$-34.2M +31.3%	$-49.7M	—

AI Insight: OMDA Financial Trends

Omada Health achieved debt-free status and delivered a profitable Q4 2025, but Q1 2026 swung back to operating losses with sharply negative operating cash flow.

• Total debt collapsed from $30M in Q2 2025 to $0M by Q3 2025, significantly strengthening the balance sheet.

• Revenue grew steadily from $68M in Q3 2025 to $78M in Q1 2026, a 15% increase over three quarters.

• Q4 2025 marked the only profitable quarter in the dataset, with net income of $5M and op income of $3M, but Q1 2026 reversed to -$5M operating loss.

• Operating cash flow swung from +$21M in Q4 2025 to -$12M in Q1 2026, a $33M sequential deterioration.

⚠ The -$12M operating cash flow in Q1 2026 versus +$21M in Q4 2025 raises questions about working capital seasonality or one-time Q4 tailwinds.

⚠ Operating losses resumed in Q1 2026 despite rising revenue — monitor whether cost growth is outpacing top-line expansion.

⚠ Equity has grown modestly each quarter ($214M to $234M); watch whether continued losses erode this cushion without new capital raises.

AI Insight: OMDA Ratio Trends

Omada's Q4 2025 profitability surge proved fleeting, with Q1 2026 operating margin swinging back to -6.1% and ROIC collapsing to -8.2%.

• Operating margin whipsawed from -3.7% in Q3 2025 to +4.3% in Q4 2025, then reversed sharply to -6.1% in Q1 2026.

• ROIC deteriorated from +5.7% in Q4 2025 to -8.2% in Q1 2026, the weakest reading in the visible dataset.

• Leverage appears minimal, with D/E at 0.14 in Q2 2025 and 0.00 in Q3–Q4 2025; Q1 2026 data unavailable.

⚠ Q4 2025 profitability looks like a one-quarter anomaly; confirm whether Q1 2026 losses reflect seasonality or structural margin pressure.

⚠ Sparse data across only three quarters makes trend extrapolation unreliable — more periods needed for conviction.

Get alerted when OMDA's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Omada Health, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of OMDA

Divisadero Street Capital Management, LP
$74.0M5,887,715 sh
Revelation Capital Management, LLC
$65.5M5,208,034 sh
FMR LLC
$41.3M3,288,380 sh
NVP Associates, LLC
$31.8M2,531,000 sh
AMERICAN CENTURY COMPANIES INC
$30.9M2,456,309 sh
a16z Capital Management, L.L.C.
$29.0M2,307,284 sh
BlackRock, Inc.
$23.9M1,904,558 sh
VANGUARD CAPITAL MANAGEMENT LLC
$22.7M1,808,984 sh
LOOMIS SAYLES & CO L P
$21.5M1,712,776 sh
MORGAN STANLEY
$18.4M1,466,776 sh

Fund	Value	Shares
Divisadero Street Capital Management, LP	$74.0M	5,887,715
Revelation Capital Management, LLC	$65.5M	5,208,034
FMR LLC	$41.3M	3,288,380
NVP Associates, LLC	$31.8M	2,531,000
AMERICAN CENTURY COMPANIES INC	$30.9M	2,456,309
a16z Capital Management, L.L.C.	$29.0M	2,307,284
BlackRock, Inc.	$23.9M	1,904,558
VANGUARD CAPITAL MANAGEMENT LLC	$22.7M	1,808,984
LOOMIS SAYLES & CO L P	$21.5M	1,712,776
MORGAN STANLEY	$18.4M	1,466,776

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put OMDA on your watchlist

Track score changes the day Omada Health, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is OMDA a good stock to buy?

13F Pro's AI-powered analysis of Omada Health, Inc. (OMDA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for OMDA are available on the OMDA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own OMDA?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling OMDA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Omada Health, Inc.'s investment landscape.